Article Text

PDF

Treatment patterns and medication adherence of patients with glaucoma in South Korea
  1. Chan Yun Kim1,
  2. Ki Ho Park2,
  3. Jaehong Ahn3,
  4. Myung-Douk Ahn4,
  5. Soon Cheol Cha5,
  6. Ho Soong Kim6,
  7. Joon Mo Kim7,
  8. Moon Jung Kim8,
  9. Tae-Woo Kim9,
  10. Yong Yeon Kim10,
  11. Ji Woong Lee11,
  12. Sang-Woo Park12,
  13. Yong Ho Sohn13,
  14. Kyung Rim Sung14,
  15. Chungkwon Yoo15,
  16. Jinhye Cha16,
  17. Young-Joo Kim16
  1. 1Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea
  2. 2Department of Ophthalmology, Seoul National University Hospital, Seoul, Republic of Korea
  3. 3Ajou University School of Medicine, Suwon, Republic of Korea
  4. 4Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea
  5. 5Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Republic of Korea
  6. 6Sungmo Eye Hospital, Busan, Republic of Korea
  7. 7Department of Ophthalmology, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul, Republic of Korea
  8. 8Kong Eye Clinic, Seoul, Republic of Korea
  9. 9Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea
  10. 10Korea University Guro Hospital, Seoul, Republic of Korea
  11. 11Pusan National University Hospital, Busan, Republic of Korea
  12. 12Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea
  13. 13Kim's Eye Hospital, Seoul, Republic of Korea
  14. 14Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
  15. 15Korea University Anam Hospital, Seoul, Republic of Korea
  16. 16Pfizer Pharmaceutical Korea Limited, Seoul, Republic of Korea
  1. Correspondence to Dr Ki Ho Park, Department of Ophthalmology, Seoul National University Hospital, 28 Yongon-dong Chongno-gu, Seoul 110-744, Republic of Korea; kihopark{at}snu.ac.kr

Abstract

Background/aims This study aimed to investigate treatment patterns and medication adherence of glaucoma. It also identified key factors associated with non-adherence.

Methods It was a cross-sectional, observational study. Patients who use eye-drops for ≤2 years were recruited at 15 eye clinics from March to November 2013. Data were collected through self-administered questionnaires and medical chart review. Medication adherence was evaluated using patients’ self-report on pill count and defined as patients’ administering drug for ≥80% of prescribed days. Medication adherence rate was calculated by dividing actual number of administration from total prescribed number of administration for 7 days. Patients whose self-reported prescription was different from total daily doses of physicians' prescription were considered as non-adherent.

Results A total of 1050 patients included, and medication adherence rate was evaluated in 1046 patients whose verification of adherence was available. Of the total, 27.4% were non-adherent, and the medication adherence rates of the total, the adherent, and the non-adherent were 90.6±17.8%, 96.8±5.5% and 56.6±24.7%, respectively. The most commonly used medication was prostaglandin (PGA) alone and the second was combination of two-class (β-blocker and carbonic anhydrase inhibitor (CAI)) and three-class combination of PGA, β-blocker and CAI followed. In multivariate analysis, the risk of non-adherence was 1.466 times greater in males than in females (95% CI 1.106 to 1.943) and 1.328-fold greater as the daily number of administration was increased (95% CI 1.186 to 1.487).

Conclusion Approximately, one-third of the patients were non-adherent, and males and increased daily number of administration were associated with non-adherence. It highlights that more systematic treatment strategies should be considered for better medication adherence, leading to effective glaucoma management.

  • Glaucoma
  • Treatment Medical

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors All authors have made substantive intellectual contributions in the study, including study design, data acquisition and/or the analysis or interpretation of data and final review of the manuscript.

  • Funding This study was sponsored by Pfizer Pharmaceuticals Korea.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study protocol was approved by institutional review boards in each medical institution involved in this study.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.